Categories: News

A NEW CHAPTER FOR OCEANCO: NEW SHAREHOLDER GABE NEWELL

ALBLASSERDAM, Netherlands, Aug. 1, 2025 /PRNewswire/ — Oceanco, one of the world’s leading custom yacht builders, is entering a new chapter with Gabe Newell – founder of Valve, tech pioneer, and longtime supporter.

- Advertisement -

Over the past 15 years, under the stewardship of the Barwani family, Oceanco has delivered some of the most iconic yachts — including Kaos, Bravo Eugenia, Black Pearl and Koru. With this foundation in place, it’s time for Oceanco’s next ownership. The Barwani family will remain active in the yachting world through their continued ownership of Turquoise Yachts, the leading Turkish custom yacht builder.

- Advertisement -

Gabe Newell is not entering this world as a financier or a strategist, but as a hands-on visionary who respects the sea, the craft, and above all, the people who make it possible. He wants Oceanco to continue on what it already does best: placing people first. This is not about buying a yacht company. It’s about plugging into a team and exploring what kind of future they can create when nothing holds them back.

- Advertisement -

Human-first. Ocean-minded. Future-focused.

- Advertisement -

Welcome to Oceanco’s next journey.

- Advertisement -

IMAGES

- Advertisement -

A selection of images are available for download here

- Advertisement -

CONTACT
Paris Baloumis, Group Marketing Director
Paris.Baloumis@oceanco.mc/+31 78 69 95 399
www.builtbyoceanco.com

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/a-new-chapter-for-oceanco-new-shareholder-gabe-newell-302517589.html

- Advertisement -

Recent Posts

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction,…

3 hours ago

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as…

3 hours ago

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)…

3 hours ago

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

June 05, 2026 20:13 ET  | Source: Bluejay Diagnostics, Inc. $8.5 million upfront with up…

3 hours ago